1. Signaling Pathways
  2. GPCR/G Protein
  3. GLP Receptor
  4. GLP Receptor Agonist

GLP Receptor Agonist

GLP Receptor Agonists (46):

Cat. No. Product Name Effect Purity
  • HY-P1731B
    Tirzepatide hydrochloride
    Agonist 99.96%
    Tirzepatide hydrochloride (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide hydrochloride has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity.
  • HY-P3506
    Retatrutide
    Agonist 99.89%
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
  • HY-P1731
    Tirzepatide
    Agonist 99.75%
    Tirzepatide (LY3298176) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity.
  • HY-P4146
    Survodutide
    Agonist 99.98%
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
  • HY-P10032A
    NN1177 TFA
    Agonist
    NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
  • HY-P10031A
    SAR441255 TFA
    Agonist 99.65%
    SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys.
  • HY-P10302
    GLP-1R/GIPR agonist-1
    Agonist
    GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
  • HY-P3506A
    Retatrutide TFA
    Agonist 99.31%
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity.
  • HY-P3375
    Mazdutide
    Agonist 99.74%
    Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D).
  • HY-147625
    GLP-1R agonist 12
    Agonist
    GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research.
  • HY-P4146A
    Survodutide TFA
    Agonist 99.62%
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.
  • HY-147623
    GLP-1R agonist 10
    Agonist 98.99%
    GLP-1R agonist 10 (Compound 109a) is a GLP-1 agonist with an EC50 of 0.051 nM.
  • HY-153816
    GLP-1 receptor agonist 12
    Agonist
    GLP-1 receptor agonist 12 (compound 20A) is an agonist of GLP Receptor. GLP-1 receptor agonist 12 can be used in the study of diseases such as diabetes.
  • HY-153815
    GLP-1 receptor agonist 11
    Agonist 98.01%
    GLP-1 receptor agonist 11 (compound 3) is an agonist of GLP Receptor. GLP-1 receptor agonist 11 can be used in the study of diseases such as diabetes and non-alc. fatty liver disease.
  • HY-153798
    GLP-1 receptor agonist 10
    Agonist 99.51%
    GLP-1 receptor agonist 10 (compound 42) is an agonist of GLP Receptor. GLP-1 receptor agonist 10 inhibits food intake and reduces glucose excursion in mice. GLP-1 receptor agonist 10 can be used in the study of type 2 diabetes (T2DM) and obesity.
  • HY-P10018
    Bamadutide
    Agonist 99.96%
    Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research.
  • HY-108795A
    Albiglutide fragment TFA
    Agonist 99.12%
    Albiglutide fragment (GLP-1 (7-36) analog) TFA is an active fragment of Albiglutide (7-36) and a glucagon-like peptide-1 (GLP-1) analog (a long-acting GLP-1 receptor agonist). Albiglutide is produced by the fusion of DPP-4 resistant GLP-1 dimer with the human albumin gene. Moreover, Albiglutide fragment TFA significantly reduces glycosylated hemoglobin (A1C) and is used in type 2 diabetes (T2D) studies.
  • HY-155147
    GLP-1 receptor agonist 13
    Agonist
    GLP-1 receptor agonist 13 (compound (S)-9) is a glucagon GLP-1 receptor agonist with EC50 of 76 nM.
  • HY-P1731A
    Tirzepatide TFA
    Agonist 98.84%
    Tirzepatide TFA (LY3298176 hydrochloride) is a glucose-dependent insulin nutritive polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist. Tirzepatide TFA has neuroprotective effects and can be used in the study of type 2 diabetes, diabetes-related neuropathy and obesity.
  • HY-P3495
    Pegapamodutide
    Agonist
    Pegapamodutide (LY-2944876) is a glucagon-GLP-1 receptor agonist, and can be used in type 2 diabetes and obesity research.